Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NormOxys Inc.

This article was originally published in Start Up

Executive Summary

The founders of NormOxys are working to commercialize molecules similar to those that give migratory birds the fortitude to fly thousands of miles. When the compound inositol pentaphosphate binds to the protein hemoglobin, its presence helps release up to three of the four oxygen molecules that hemoglobin picks up in the lungs and carries out to the body. NormOxys is betting that its lead candidate can help elevate oxygen levels in human tissues that lack it, and so become a treatment for a range of disorders, from heart failure to diabetic retinopathy, traumatic blood loss, and even cancer.

You may also be interested in...

Start-Up Previews (06/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. "Altering The Insulin Resistance System" features profiles of Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia BIotech and Rhythm Pharmaceuticals. Plus these Start-Ups Across Health Care: nContact Surgical, NormOxys and Thermopeutix.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts